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Abstract: Cardiac MR (CMR) derived ventricular variables are predictive of mortality in pulmonary 
arterial hypertension (PAH). Rodent models which emphasize ventricular function, allowing serial 
monitoring are needed to identify pathophysiological features and novel therapies for PAH. We 
investigated longitudinal changes in the Sugen-hypoxia (SuHx) model during disease progression. 
Sprague Dawley rats (n=32) were divided into 2 groups. 1)Sugen-hypoxia; a dose of subcutaneous 
Sugen-5416 and placed in hypobaric hypoxia for 2 weeks followed by normoxia for 3 weeks. 
2)Normoxia; maintained at normal pressure for 5 weeks. Rats were examined at 5 or 8 weeks with 
right-heart catheter, CMR and autopsy. Compared to normoxic controls (23.9±4.1 mmHg) RV systolic 
pressure was elevated in SuHx rats at 5 and 8 weeks (40.9±15.5 mmHg p=0.026, 48.9±9.6 mmHg 
p=0.002). RV end-systolic volume index was increased in 8 weeks SuHx (0.28±0.04 mlcm-2 p=0.003) 
compared to normoxic controls (0.18±0.03 mlcm-2). There was progressive dilatation of the RV at 8 
weeks SuHx compared to normoxic controls (0.75±0.13 mlcm-2 vs 0.56±0.1 mlcm-2 p=0.02). 
Ventricular mass index by CMR at 5 weeks (0.34±0.06 vs p=0.003) and 8 weeks SuHx (0.34±0.06 
p=0.002) were higher than normoxic controls (0.21 ± 0.04). Stroke volume, RV ejection fraction and 
LV variables were preserved in SuHx. Ventricular changes during the course of illness in a PAH rodent 
model can be examined by CMR. These changes including RV hypertrophy and subsequent dilatation 
are similar to those seen in PAH patients. Despite the persisting PH, there are features of adaptive 
cardiac remodelling through the study duration. 






Pulmonary arterial hypertension (PAH) is a disease of the pulmonary vasculature, however, it 
is subsequent right ventricular (RV) failure that is the main cause of morbidity and mortality 
in patients. Cardiac magnetic resonance (CMR) is a non-invasive imaging tool providing high-
resolution three-dimensional images of the heart. During CMR ventricular short axis stacks 
are used to reconstruct a 3D image of the right and the left ventricle (LV) and ventricular 
volumes, mass and function can be measured.1 Many CMR measurements have shown to be 
strongly predictive of mortality and survival thus offering potential for assessing response to 
treatment. Stroke volume 2, right ventricular ejection fraction 3, right and left ventricular end 
diastolic volume 4 have all shown to be prognostic markers in PAH patients.  
Small animal (rodent) models are increasingly used to identify pathophysiology as well as 
therapies for PAH with the intention of translating findings to humans. Accurate monitoring 
of disease in rodents with emphasis on ventricular function (rather than right heart 
catheterization alone) without killing the animal is needed.  
Various rodent models to recapitulate human PAH have been produced. Sugen-5416 (Sugen), 
an inhibitor of vascular endothelial growth factor (VEGF) was shown to cause a mild rise in 
pulmonary artery pressure in wild type rats. Combining Sugen with another stimulus of PH 
i.e. chronic hypoxia, Taraseviciene-Stewart et al described the Sugen-hypoxia (SuHx) rat 
model in 2001.5 A combination of Sugen and chronic hypoxia cause pulmonary endothelial 
cell death and severe PH. Subsequently in 2010, Abe et al showed that SuHx rats 
demonstrated evidence of severe pulmonary arteriopathy including concentric neo-intimal 
and complex plexiform-like lesions which closely resemble plexiform lesions seen in humans.6 
Subsequently, other groups have attempted to characterize hemodynamics in a SuHx model 
beyond right heart catheterization alone. Vitali et al, evaluated longitudinal changes in a SuHx 
mouse model of PH. Echocardiographic and invasive measurements were performed after 3 
weeks of hypoxia and after 10 weeks of recovery in normoxia. Ten weeks after hypoxic 
exposure, RV systolic pressure (RVSP) had decreased, but remained elevated compared to 
normoxic controls. However, RV hypertrophy had resolved. They observed very few angio-
obliterative lesions at 10 weeks.7 De Raaf et al used telemetry to characterize hemodynamics 
in SuHx rats and associated these with serial histology.8 Jones et al demonstrated a good 
correlation between M-mode and Doppler Echo vs. right heart catheterization in the 
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monocrotaline rat model.9 In a study by Urboniene et al assessing validation of high resolution 
echocardiography and CMR vs high fidelity catheterisation in experimental PH monocrotaline 
rat model, non-invasive measures of RV free wall thickness/mass correlated well with post 
mortem measurements.10  
Our group has a proven track record using CMR imaging to evaluate RV function in humans 
with PAH 4, 11, 12. The same non-invasive and repeatable measurements would be of great 
advantage for the study of rodent models to allow a detailed understanding of ventricular 
structural and functional changes that occur, to enhance efficacy in translational medicine. 
We investigated whether CMR is feasible in a SuHx rat model of PH. Subsequently we 
investigated the structural and functional changes associated with the model during disease 
progression. Finally, we discussed the suitability of the SuHx model for translational studies 
of the mechanisms of RV dysfunction in PAH.  
Method 
Ethics 
All experimental procedures were carried out in accordance with the United Kingdom Animal 
Procedures Act (1986) and with the US NIH publication No. 85-23, revised 1996, and ethical 
approval was also granted by the University of Glasgow Ethics Committee. Rodents were 
housed in a 12-hour light dark cycle with access to food and water ad libitum. 
Study design 
Male Sprague Dawley rats (three weeks) (n=32) were divided into two groups (n=16 in each 
group). Group 1) Sugen-hypoxia - a single dose of subcutaneous Sugen-5416 (Sigma, UK) 
suspended in vehicle (20mg/kg)), before being placed in a hypobaric chamber (atmospheric 
pressure 550 mbar) for 2 weeks and then placed in normal room pressure (1013 mbar) for 3 
weeks whilst PH developed. Group 2) Normoxia maintained at normal room pressure for 5 
weeks. In each group (n=16) half the animals entered the CMR arm of the study (n=8) while 
the other half underwent right heart catheterization for hemodynamic assessment (n=8). 
Animals were assessed at five weeks and eight weeks from the beginning of the study. The 
study design is summarized in Figure 1.  
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In vivo hemodynamic measurements 
Animals were anesthetically induced with 3% (v/v) isoflurane and then maintained at 2% (v/v) 
isoflurane supplemented with a constant flow of 5% (v/v) oxygen. Hemodynamic 
measurements were taken using an ultra-miniature Polyimide Nylon catheter capable of 
measuring ventricular pressure continuously (AD instruments spr-869NR, Millar). The 
catheter was used as per the manufacturer’s instructions with the PowerLab 35 Series data 
acquisition system with LabChart Pro and the pressure volume (PV) Loop analysis module. For 
right heart pressure analysis, the catheter was inserted into the jugular vein and guided into 
the RV to measure RVSP.   
RV hypertrophy and tissue harvest 
Following hemodynamic assessment, animals were culled and hearts flushed with PBS using 
a blunt needle to clear peripheral blood cells. Euthanasia consisted of an overdose of 
anaesthetic followed by a schedule 1 kill (cervical dislocation). The heart was isolated, atria 
removed and tissue fixed with 10% (v/v) neutral buffered formalin (NBF) for 48 hours before 
paraffin processing for histological analysis by immunohistochemistry. Tissue was sectioned 
by microtome at width of 5µm and stained by Gomori's Trichrome staining kit (Atom 
Scientific, Manchester, UK) as per manufacturer’s instructions. 
Gross anatomy postpartum 
After the heart was isolated and atria removed, the RV and LV weights were obtained to 
determine RV hypertrophy. Interventricular septum was considered part of the LV.  
Pulmonary vascular remodeling 
 
Vascular thickening was determined by smooth muscle actin antibody (ab5694, Abcam, 
Cambridge, UK) staining, thickening was characterized by an increase in the vessel wall 
diameter of more than 50% of the arterial wall or complete occlusion. The number of 
remodeled vessels over the total number of vessels present in a lung section was determined. 
Sections were analyzed in a blinded manner. 
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CMR 
CMR imaging was performed in a Bruker Biospec 7-T/30-cm (Bruker Biospin, Ettlingen, 
Germany) system with a gradient coil insert (400 mT/m). Using a 72mm transmit birdcage 
resonator and 4 channel phased array rat cardiac receiver coil. Anesthesia was induced with 
gas flow at 2–3 l/min, and the isoflurane delivered via a vaporizer (Vetamac, Rossville, IN) at 
3–4%. The exhaust was connected to the Omnicon F/Air device (AM Bickford). After induction, 
animals were maintained at 2% (v/v) isoflurane supplemented with a constant flow of 5% 
(v/v) oxygen. An external water jacket was used to maintain a core temperature of 37°C. 
During all procedures, body temperature, ECG, and respiration were monitored (Echo: Indus 
Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: Powerlab, Ad 
instruments, Colorado Springs, CO). Long and short axis scout images were acquired so that 
short axis images could be planned using a segmented, cardiac – triggered FLASH sequence. 
The images were acquired with a slice thickness of 1.5mm ensuring the entire biventricular 
length is covered. The CMR parameters were as follows. Slice thickness-1.50mm, field of 
View-30.00mm x 30.00mm, image matrix-192 x 192 pixels, image resolution-156μm x 156μm, 
Flip angle-15 degrees, Echo time-2.50ms, Rep. time-7.02ms, number of frames-25, number of 
averages-6, software version-Paravision 5.1. 
CMR analysis 
Scans were coded by number and analyzed in batches by G.J who was blinded to the identity 
and hemodynamic results at the time of analysis. A second observer (A.U) analyzed 5 scans 
for inter-rater agreement analysis. Trabeculations and papillary muscles were considered as 
part of the blood pool. The epicardial and endocardial borders were manually outlined in end-
diastolic and end-systolic frames using Qmass (MEDIS, Netherlands). Stroke volume was 
determined from end diastolic volume (EDV) – end systolic volume (ESV) of the LV. Ejection 
fraction [(SV/EDV)*100%] was also determined. RV and LV masses were determined by 
manual planimetry at diastole. Ventricular mass index (VMI) was defined as the ratio between 
RV to LV mass, with the interventricular septum considered part of the LV. LV eccentricity 
index (LVEI) was defined as the ratio between maximum anterior-posterior to septal lateral 
diameters of the LV and was measured at both systole and diastole. All ventricular volumes 
and mass measurements were indexed to body surface area.13 
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Statistical analysis 
Ventricular volumes and mass are given as µlcm-2 and mgcm-2 respectively indexed for body 
surface area. Statistical analysis was performed using SPSS (IBM, SPSS Statistics, USA) and 
Graphpad Prism (Graphpad, USA). A significance level of 0.05 was employed for statistical 
tests. An analysis of variance test was used to compare RV and LV mass, volumes and function 
between normoxic animals and different stages of SuHx. If there was statistical significance a 
Tukey test was used for post hoc analysis. To compare different methods of ventricular mass 
index measurement (CMR vs autopsy) a spearmen correlation was used.  Inter-rater 
variability for determination of LV and RV function were calculated from paired 
measurements of the LV ejection fraction (LVEF) and RV ejection fraction (RVEF) of two 
readers as interclass correlation coefficient with a two-way mixed model for absolute 
agreement. Results are shown as mean +/- SD unless otherwise stated. 
Results  
Right heart catheterization and RV hypertrophy  
Compared to normoxic rats (23.87 ± 4.1 mmHg) RVSP was significantly elevated in SuHx rats 
at both five and eight weeks (40.95 ± 15.5 mmHg p=0.03, 48.89 ± 9.6 mmHg p=0.002 
respectively). There were no significant differences in RVSP between SuHx rats at five and 
eight weeks. Similarly, relative RV mass measured at autopsy by RV / (LV + septum) was 
significantly elevated at five week (0.36 ± 0.1 p=0.021) and eight week (0.4 ± 0.04 p=0.004) 
SuHx compared to controls (0.25 ± 0.04). (Figure 2) Immunohistochemical analysis of α-
smooth muscle actin staining in the smooth muscle layer of small pulmonary arteries of the 
lungs demonstrated vascular thickening and remodeling at both 5 and 8 weeks of SuHx. 
Although there was statistical significant difference between the percentage of remodeled 
vessels between normoxia and SuHx groups (57.4% ± 7.3 vs 77.6% ± 10.3 p=0.02, 57.4% ± 7.3 
vs 78.5% ± 9.4 p=0.02), there was no significant difference observed between SuHx rats at 





A representative long axis image (A) and a short axis cine stack (B-F) are shown in Figure 3. 
The LV and the RV demonstrated good spatial and temporal resolution allowing manual 
planimetry. All of the images in normoxic or SuHx animals were suitable for analysis. Initial 
scout images were acquired to identify the cardiac chambers.  
Inter-rater variability 
There was excellent agreement between the two observers (ICC 0.97, 95%CI 0.74 to 1.0) for 
LVEF as well as for RVEF (ICC 0.96, 95%CI 0.64 to 1.0).  
Right ventricle 
RV end systolic volume index (RVESVI) was significantly increased in SuHx rats at 8 weeks (0.28 
± 0.04 p=0.003) compared to normoxic rats (0.18 ± 0.03). There were no significant 
differences between normoxia and SuHx at five weeks. Compared to normoxic rats (0.17 ± 
0.03), RV mass index was increased in the SuHx rats at five weeks (0.28 ± 0.04 p=0.002) and 
eight weeks (0.27 ± 0.04 p=0.002). RV demonstrated progressive dilatation (increasing RV end 
diastolic volume index – RVEDVI) at eight weeks of SuHx compared to normoxic rats (0.75 ± 
0.13 vs 0.56 ± 0.1 p=0.022). In RVEF, there were no significant differences between normoxic 
rats and 5 and 8 week SuHx rats however demonstrating trends towards impairment (RVEF = 
68.3 ± 5.1%, 69.4 ± 6.9% and 62.6 ± 6.1 % respectively). Stroke volume index was preserved 
in the SuHx model at five and eight weeks compared to normoxia (0.44 ± 0.1 vs 0.5 ± 0.04 vs 
0.49 ± 0.1). Ventricular mass index (VMI) after five weeks (0.34 ± 0.06 p=0.003) and eight 
weeks of SuHx (0.34 ± 0.06 p = 0.002) were significantly higher than normoxic rats (0.21 ± 
0.04). (Figure 4)  
Left ventricle 
No differences were observed between the normoxic and SuHx groups (normoxia, 5 and 8 
weeks respectively) in terms of LV end diastolic volume index (0.73 ± 0.08 vs 0.74 ± 0.06 vs 
0.75 ± 0.16), LV end systolic volume index (0.29 ± 0.05 vs 0.24 ± 0.04 vs 0.25 ± 0.03), LV mass 
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index (0.79 ± 0.07 vs 0.82 ± 0.09 vs 0.8 ± 0.15) or LVEF (60.3 ± 7.03 vs 67.8 ± 3.16 vs 66.5 ± 
3.12). (Figure 5)  
LV eccentricity index (LVEI) 
LVEI measured at systole was significantly higher in SuHx rats at five weeks (1.2 ± 0.07 
p=0.006) and in SuHx rats at eight weeks (1.22 ± 0.14 p=0.004) compared to normoxic rats 
(0.98 ± 0.08).  There were no differences between LVEI at diastole between normoxia and 
SuHx at 5 or 8 weeks (1.06 ± 0.05 vs 1.14 ± 0.04 vs 1.1 ± 0.06).  (Figure 5)  
Supplementary file demonstrates CMR variables between normoxia and Sugen hypoxia at 5 
and 8 weeks.  
Autopsy vs CMR in the measurement of RV hypertrophy 
CMR images taken from a normoxic and SuHx animal and light microscopy images of the same 
animals at autopsy were compared. Although both techniques could visually demonstrate 
ventricular size and wall thickness (hypertrophy), CMR demonstrated functional aspects of RV 
contraction including septal flattening and paradoxical septal motion during systole in SuHx 
animals. Figure 6 demonstrates short axis CMR images (A, B and C) and light microscopy 
images (D and E) of short axis sections of the same rat hearts at autopsy. B and C 
demonstrates a SuHx animal at the same short axis at diastole (B) and systole (C). The SuHx 
animal demonstrated a significantly dilated and hypertrophied RV with paradoxical septal 
motion at systole. There was very good correlation between VMI measured by CMR vs 
autopsy (Spearmen r = 0.8328 95% CI 0.5633 to 0.9422 p < 0.0001). However, MR images 
demonstrate functional aspects of RV contraction including septal flattening and paradoxical 
septal motion during systole due to RV pressure overload.   
Discussion 
To best of our knowledge, this is the first study demonstrating longitudinal biventricular mass, 
volume and function in a PH animal model using CMR. Previous studies had used 
echocardiography to examine biventricular function and structure in small animal models of 
PAH 7. Previous CMR studies used phase contrast imaging but did not explore LV and RV 
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volume and functional variables known to be prognostic in PH, nor look at longitudinal 
changes.10  
Our study demonstrated the feasibility of CMR in a small animal model of PAH with good 
spatial and temporal resolution and excellent inter-observer reproducibility. The future 
advantage of CMR over cardiac catheterization and autopsy is the ability to perform imaging 
serially on the same animal to look at disease progression and response to treatment without 
killing the animal.  
The main cause of morbidity and mortality in patients with PAH is RV failure. It had been 
assumed that the cause of RV dysfunction was alterations to the pulmonary vasculature and 
therefore treatment focus had been centered on improving pulmonary hemodynamics, with 
the assumption that improvement in RV would follow. However, it is now evident that cardiac 
response to a given level of pulmonary hemodynamic overload is variable but important in 
the subsequent prognosis of these patients.3  Although traditionally right heart 
catheterization and post mortem studies have been used, there is a need for non-invasive 
tests of RV function in animal models of PAH. In addition, we need to have a better 
understanding of the longitudinal changes in ventricular function in animal models of PAH.  
Although the RV is the obvious focus of attention, LV dysfunction can occur through cardiac 
interaction thus simultaneous evaluation of the LV is important. Echocardiography is widely 
available and can be used to estimate RVSP, however imaging of the RV with its complex 
geometry is difficult.  
The SuHx small animal model – pulmonary hypertension  
Plexiform lesions in the pulmonary vasculature are known to be the hallmark of PAH and 
attempts have been made to establish an animal model that closely mimic human disease. 
The SuHx model has been shown to cause severe PH with the development of plexiform 
lesions. We used a SuHx model consisting of an injection of Sugen, 2 weeks of hypobaric 
hypoxia and 3 weeks or normoxia. Dean et al explored the effects of Metformin on the 
development of PH via Aromatase inhibition, a similar SuHx model was used (Sugen + 2 weeks 
of hypobaric hypoxia and 3 weeks of normoxia).14 The study demonstrated similar 
hemodynamics and RV hypertrophy compared to our study population after 8 weeks. Abe et 
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al investigated the longitudinal hemodynamic and histological changes in the model.  At 13 
to 14 weeks after Sugen, the rats had very high RVSP (96+/- 11 vs 21) and  severe RV 
hypertrophy (0.76 at five weeks, 0.74 at 8 weeks and 0.74 at 13-14 weeks).6 The varying 
degrees of RVSP and RV hypertrophy in these studies, is likely related to the duration of 
exposure to hypoxia, however, could also be related to the animal strain, gender and age at 
exposure.  
The SuHx small animal model – RV function 
In humans with PAH, progressive narrowing of the pulmonary vasculature causes increased 
load to the RV. The RV adaptation results in increasing wall thickness (hypertrophy) and 
contractility (coupling). Ventriculo-arterial coupling preserves stroke volume and ventricular 
efficiency. The RV then dilates, increasing wall stress and oxygen consumption per gram 
resulting in uncoupling and reduced stroke volume.15 In our study, RV hypertrophy was 
followed by subsequent dilatation. However, stroke volume and RVEF were relatively 
preserved.  This was despite the presence of persistently elevated RVSP. We believe this study 
represents the natural history of RV hypertrophy and failure, demonstrating compensated RV 
hypertrophy (adaptive remodeling) before progression into maladaptive remodeling with 
further RV dilatation and RV failure, with reduction of RV output.  
Adaptive vs maladaptive remodeling 
Wang et al hypothesized that a SuHx mouse model may capture the transition from adaptive 
to maladaptive RV remodeling including impairment in RV function by studying pressure 
volume measurements in vivo. The results suggested that RV remodeling may begin to shift 
from adaptive to maladaptive with increasing duration of SuHx exposure. However, for the 
duration of SuHx exposure used in their study, no drop in cardiac output was observed.16 We 
believe that our study demonstrates a period of adaptive remodeling of the RV with 
compensated hypertrophy with minimal RV dilatation at later stages of the study. By 
lengthening the exposure to SuHx we may be able to identify the transition from adaptive to 
maladaptive remodeling and identify decompensated right heart failure in this model. Most 
patients present to clinical assessment when there are signs of more severe RV dysfunction 
and in contrast pre-clinical SuHx model demonstrate adaptive remodeling at least early in its 
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disease progression. This is of importance in the design of pre-clinical studies as intervention 
with experimental therapeutics is likely to occur at this early adaptive stage of disease 
progression where RV function/stroke volume seem to be preserved despite the presence of 
PAH.   
Small animal model - LV function 
In PAH, impaired LV performance is explained by low RV cardiac output and direct ventricular 
interaction due to inter-ventricular dyssynchrony and paradoxical septal motion.17, 18 Previous 
human studies have demonstrated that patients with progressive illness demonstrated lower 
LV systolic function compared to stable patients. Previous echocardiography studies have also 
demonstrated impaired LV strain and torsion in PAH patients.17 We observed preserved LV 
systolic function with preserved LV mass and volume variables in this small animal model of 
PAH. Although PAH animals demonstrated paradoxical septal motion of the septum in our 
study, preserved RV output probably explains the preserved LV function.  
Conclusion 
CMR is feasible in a small animal model of PAH and could be used in pre-clinical animal studies 
to explore bi-ventricular structural and functional changes during the course of illness. It is 
likely that the SuHx model demonstrates adaptive remodeling to persistently elevated 
pulmonary pressures which is demonstrable by preserved RV function and stroke volume with 
hypertrophy of the RV. Further longitudinal studies are required to assess this model in detail, 
especially focusing on longitudinal RV response. The search for better animal models of PH 
continues because our understanding of the pathobiology of disease and the development of 
new therapeutic strategies depends on robust animal models, but at present no single model 
has all the features of human disease. 
Limitations 
The study assessed rats at 5 and 8 weeks from Sugen exposure, while assessment later may 
have demonstrated worsened hemodynamics and RV variables mimicking disease 
presentation in humans. The rats were anaesthetized with Isoflurane, previous studies using 
halogenated anesthetics have been shown to impair RV-PA coupling, however these effects 
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were seen both in hypoxia and hyperoxia.19 Future studies with late gadolinium enhancement 
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Supplementary file. Cardiac MRI variables between normoxia, 5 week Sugen hypoxia (SuHx 
5 wk) and 8 week Sugen hypoxia (SuHx 8 wk) are demonstrated. Ventricular volumes and 
mass are given as µl and mg, and as µlcm-2 and mgcm-2 respectively when indexed for body 
surface area. LV ejection fraction (LVEF), LV end diastolic volume (LVEDV), LV end diastolic 
volume index (LVEDVI), LV end systolic volume (LVESV), LV end systolic volume index 
(LVESVI), stroke volume (SV), stroke volume index (SVI), RV ejection fraction (RVEF), RV end 
diastolic volume (RVEDV), RV end diastolic volume index (RVEDVI), RV end systolic volume 
(RVESV), RV end systolic volume index (RVESVI), LV eccentricity index (LVEI) at systole and 
diastole are shown. All values are shown as mean ± standard deviation (95 % confidence 
interval). 
 
Normoxia SuHx 5 wk SuHx 8 wk 
Weight (g) 411.4 ± 50.8 ( 368.9 - 453.9 )  311.3 ± 8.5 ( 297.8 - 324.7 ) 424.3 ± 55.7 ( 335.7 - 512. 8 ) 
LVEF 60.3 ± 7 ( 54.4 - 66.2 ) 67.8 ± 3.2 ( 62.8 - 72.8 )  66.5 ± 3.1 ( 61.5 - 71.5 )  
LVEDV 393.7 ± 50.8 ( 351.3 - 436.2 )  332.6 ± 28.7 ( 286.9 - 378.3 )  410.7 ± 63 ( 310.4 - 510.9 ) 
LVEDVI 0.73 ± 0.08 ( 0.66 - 0.8 )  0.74 ± 0.06 ( 0.64 - 0.84 ) 0.75 ± 0.16 ( 0.5 – 1 ) 
LVESV 155.9 ± 33.8 ( 127.6 - 184.1 ) 107.4 ± 16.8 ( 80.6 - 134.1 )  136.3 ± 11.6 ( 117.8 - 154.8 ) 
LVESVI 0.29 ± 0.05 ( 0.24 - 0.33 )  0.24 ± 0.04 ( 0.18 - 0.3 )  0.25 ± 0.03 ( 0.2 - 0.29 )  
SV (LV)  237.8 ± 44.8 ( 200.4 - 275.3 )  225.3 ± 17.3 ( 197.8 - 252.7 ) 274.3 ± 53.5 ( 189.2 - 359.4 ) 
SVI 0.44 ± 0.1 ( 0.37 - 0.51 )  0.5 ± 0.04 ( 0.45 - 0.55 )  0.49 ± 0.1 ( 0.3 - 0.69 ) 
LV mass 426.6 ± 55 ( 380.6 - 472.6 ) 371.1 ± 46 ( 298 - 444.3 )  440.4 ± 48.4 ( 363.4 - 517.4 ) 
LV mass index 0.79 ± 0.07 ( 0.72 - 0.84 )  0.82 ± 0.09 ( 0.68 - 0.96 ) 0.8 ± 0.15 ( 0.56 - 1.04 )  
RVEF 68.3 ± 5.1 ( 64.1 - 72.5 ) 69.4 ± 6.9 ( 58.4 - 80.3 ) 62.6 ± 6.1 ( 52.9 - 72.3 ) 
RVEDV 303.5 ± 49.4 ( 262.3 - 344.8 )  316.6 ± 16.6 ( 290.2 - 343 ) 409.1 ± 46.8 ( 334.6 - 483.7 ) 
RVEDVI 0.56 ± 0.1 ( 0.48 - 0.64 ) 0.7 ± 0.03 ( 0.66 - 0.75 )  0.75 ± 0.13 ( 0.54 - 0.95 )  
RVESV 95.7 ± 18.6 ( 80.1 - 111.2 )  97.5 ± 25.3 ( 57.2 - 137.7 )  151.8 ± 19.1 ( 121.4 - 182.2 )  
RVESVI 0.18 ± 0.03 ( 0.15 - 0.19 ) 0.22 ± 0.06 ( 0.12 - 0.31 )  0.28 ± 0.04 ( 0.21 - 0.34 )  
RV mass 91.2 ± 20.6 ( 73. 9 - 108.4 ) 123.3 ± 19.1 ( 93 - 153.7 )  148 ± 14 ( 125.8 - 170.3 ) 
RV mass index 0.17 ± 0.03 ( 0.14 - 0.2 )  0.28 ± 0.04 ( 0.21 - 0.34 ) 0.27 ± 0.04 ( 0.2 -0.34 ) 
Ventricular mass index (VMI) 0.21 ± 0.04 ( 0.18 - 0.24 )  0.34 ± 0.06 ( 0.24 - 0.43 )  0.34 ± 0.06 ( 0.25 - 0.43 )  
LVEI at systole 0.98 ± 0.08 ( 0.91 - 1.05 )  1.2 ± 0.07 ( 1.09 - 1.31 ) 1.22 ± 0.14 ( 0.99 - 1.45 ) 
LVEI at diastole 1.06 ± 0.05 ( 1.02 -1.1  ) 1.14 ± 0.04 ( 1.1 -1.19 ) 1.1 ± 0.06 ( 1.01 - 1.2 )  
